909637

Applied Filters:

Keyword:'909637'

Showing 1-7 of 7 results for "909637" within Papers

PLGA-based nanoparticles: an overview of biomedical applications.

Fabienne Danhier et al.

Journal of controlled release : official journal of the Controlled Release Society, 161(2), 505-522 (2012-02-23)

Poly(lactic-co-glycolic acid) (PLGA) is one of the most successfully developed biodegradable polymers. Among the different polymers developed to formulate polymeric nanoparticles, PLGA has attracted considerable attention due to its attractive properties: (i) biodegradability and biocompatibility, (ii) FDA and European Medicine

Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises.

Francesca Ungaro et al.

The Journal of pharmacy and pharmacology, 64(9), 1217-1235 (2012-08-14)

The aim of this review is to summarize the current state-of-the-art in poly(lactic-co-glycolic acid) (PLGA) carriers for inhalation. It presents the rational of use, the potential and the recent advances in developing PLGA microparticles and nanoparticles for pulmonary delivery. The

Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines.

Anil Mahapatro et al.

Journal of nanobiotechnology, 9, 55-55 (2011-11-30)

Biodegradable nanoparticles (NPs) are gaining increased attention for their ability to serve as a viable carrier for site specific delivery of vaccines, genes, drugs and other biomolecules in the body. They offer enhanced biocompatibility, superior drug/vaccine encapsulation, and convenient release

Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics.

Amit K Jain et al.

Critical reviews in therapeutic drug carrier systems, 28(1), 1-45 (2011-03-15)

Nanocarriers formulated with the US Food and Drug Administration-approved biocompatible and biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) are being widely explored for the controlled delivery of therapeutic drugs, proteins, peptides, oligonucleotides, and genes. Surface functionalization of PLGA nanoparticles has paved the

Functional PLGA NPs for oral drug delivery: recent strategies and developments.

L Martin-Banderas et al.

Mini reviews in medicinal chemistry, 13(1), 58-69 (2012-09-15)

This article presents the potential of PLGA nanoparticles for the oral administration of drugs. Different strategies are used to improve oral absorption of these nanoparticles. These strategies are based on modification of nanoparticle surface properties. They can be achieved either

Drug-loaded PLGA nanoparticles for oral administration: fundamental issues and challenges ahead.

Gaurav Kumar et al.

Critical reviews in therapeutic drug carrier systems, 29(2), 149-182 (2012-04-06)

Drug-loaded polylactide-co-glycolide (PLGA) nanoparticles have been extensively studied and have a practical impact on drug delivery. Many PLGA-based nanoformulations have reached different stages of preclinical development; however, they present distinct challenges for researchers. This review discusses some of the challenges

PLGA-based nanoparticles as cancer drug delivery systems.

Fatemeh Sadat Tabatabaei Mirakabad et al.

Asian Pacific journal of cancer prevention : APJCP, 15(2), 517-535 (2014-02-27)

Poly (lactic-co-glycolic acid) (PLGA) is one of the most effective biodegradable polymeric nanoparticles (NPs). It has been approved by the US FDA to use in drug delivery systems due to controlled and sustained- release properties, low toxicity, and biocompatibility with

Page 1 of 1